Develop personalised lifestyle and treatment strategies (such as diet changes, supplements, or medication adjustments)
Introduction Retatrutide (development code LY3437943) is an investigational single-molecule agonist reported to engage three incretin- and metabolism-related receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
Tornado diagrams were created to visualize the impact of these changes in oral semaglutide compared to placebo, with 95% confidence intervals (CIs) of the corresponding estimates and 20% of the base case values as upper and lower bounds (Shafie and Ng, 2020
Functionalized self-assembling peptide nanofiber hydrogel as a scaffold for rabbit nucleus pulposus cells
Four decades of growth hormone therapy for short children: what have we achieved
Since starting treatment, 57% of Ro patients say they feel more confident in their bodies
